Protagonist's ICOTYDE Gains FDA Approval for Psoriasis, Triggering $50M Milestone from Johnson & Johnson

on

On March 18, 2026, the U.S. FDA approved ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in eligible patients.1235

ICOTYDE is the first oral IL-23R-targeted peptide, a once-daily pill providing high efficacy (~70% IGA 0/1, 55% PASI90 at Week 16) and favorable safety in four Phase 3 trials with 2,500 patients.12

Approval triggers a $50 million milestone payment to Protagonist from Johnson & Johnson, plus up to $580 million in future milestones and 6-10% tiered royalties on global sales.12

Johnson & Johnson will commercialize ICOTYDE under their 2017 collaboration with Protagonist, who led development through Phase 1.123

The drug was jointly discovered by Protagonist and J&J scientists and targets the IL-23 receptor precisely.12

Sources:

1. https://www.stocktitan.net/news/PTGX/protagonist-therapeutics-announces-u-s-fda-approval-of-icotyde-tm-3zen5bm3pmsr.html

2. https://www.biospace.com/press-releases/protagonist-therapeutics-announces-u-s-fda-approval-of-icotydetm-icotrokinra-for-the-treatment-of-moderate-to-severe-plaque-psoriasis

3. https://www.jnj.com/media-center/press-releases/fda-approval-of-icotyde-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide

5. https://www.hmpgloballearningnetwork.com/site/thederm/fda-alerts/fda-approves-icotyde-icotrokinra-treatment-moderate-severe-plaque-psoriasis